Cite
MLA Citation
J. Gligorov et al.. “Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.” European journal of cancer, vol. 82, 2017, pp. 237–246. http://access.bl.uk/ark:/81055/vdc_100048315377.0x000019